- Home
- AII vs IVA Comparison
AII vs IVA Comparison
Compare AII & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AII
- IVA
- Stock Information
- Founded
- AII 294
- IVA 2011
- Country
- AII United States
- IVA France
- Employees
- AII N/A
- IVA N/A
- Industry
- AII Property-Casualty Insurers
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- AII Finance
- IVA Health Care
- Exchange
- AII Nasdaq
- IVA Nasdaq
- Market Cap
- AII 330.9M
- IVA 359.6M
- IPO Year
- AII 2025
- IVA 2020
- Fundamental
- Price
- AII N/A
- IVA $3.58
- Analyst Decision
- AII
- IVA Strong Buy
- Analyst Count
- AII 0
- IVA 4
- Target Price
- AII N/A
- IVA $10.50
- AVG Volume (30 Days)
- AII 1.2M
- IVA 18.0K
- Earning Date
- AII 01-01-0001
- IVA 03-26-2025
- Dividend Yield
- AII N/A
- IVA N/A
- EPS Growth
- AII N/A
- IVA N/A
- EPS
- AII 309.45
- IVA N/A
- Revenue
- AII $204,354,000.00
- IVA $14,591,573.00
- Revenue This Year
- AII N/A
- IVA $15.38
- Revenue Next Year
- AII N/A
- IVA $24.22
- P/E Ratio
- AII $0.06
- IVA N/A
- Revenue Growth
- AII 1.73
- IVA N/A
- 52 Week Low
- AII $0.59
- IVA $1.53
- 52 Week High
- AII $2.69
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- AII N/A
- IVA 54.47
- Support Level
- AII N/A
- IVA $3.48
- Resistance Level
- AII N/A
- IVA $3.77
- Average True Range (ATR)
- AII 0.00
- IVA 0.22
- MACD
- AII 0.00
- IVA -0.03
- Stochastic Oscillator
- AII 0.00
- IVA 48.68
About AII American Integrity Insurance Group Inc. Common Stock
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.